Large observational study links semaglutide to lower rates of several neurological and psychiatric outcomes, independent of weight loss

# What the study did Researchers analyzed electronic health records for 63,215 people who were treated with semaglutide and who already had at least one neurological or neuropsychiatric condition. They tracked 24 outcomes over roughly two years and compared semaglutide-treated patients with matched patients taking other diabetes medications, including metformin.

# Main findings Semaglutide use was associated with lower rates of several neuropsychiatric and neurological outcomes. Two concrete comparisons reported in the study:

• Dementia or degenerative central nervous system disease: 0.95% in semaglutide users versus 1.96% in matched metformin users.
• Mood disorders: 10.5% in semaglutide users versus 13.2% in matched metformin users.

Researchers also reported lower rates of cognitive symptoms, cerebrovascular disease, substance-related disorders and other outcomes among semaglutide users in the dataset.

# Dose pattern and weight loss Patients who reached higher doses of semaglutide generally experienced larger differences in several neuropsychiatric outcomes. That dose-related pattern is one signal scientists look for when assessing whether an observed association might reflect a real drug effect.

Importantly, the associations persisted after researchers accounted for weight loss. That suggests any link between semaglutide and the observed outcomes may involve mechanisms beyond simply losing pounds.

# Biological context Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. GLP-1 signaling is known to affect appetite and digestion, which is why these drugs reduce hunger and slow gastric emptying. But GLP-1 receptors are present in multiple systems. Researchers are investigating effects on inflammation, blood vessels, metabolism and the nervous system. Those broader biological roles help explain why investigators are testing GLP-1 drugs in areas such as addiction, neurodegenerative disease and aging.

# Why this is not proof of a brain drug The study is retrospective and observational. People were not randomly assigned to semaglutide or another medication, and medical-record comparisons can't eliminate all differences between groups (for example, baseline health, socioeconomic status or access to care). The authors also focused on people who already had neurologic or psychiatric diagnoses, so results don't automatically generalize to everyone who takes semaglutide.

Observational findings can generate hypotheses and point to areas worth testing, but they do not demonstrate causation.

# Practical takeaway for patients and clinicians These results add to growing research that GLP-1 drugs may affect systems beyond blood sugar and body weight. However, semaglutide should not be used specifically to treat dementia, depression or other neurological or psychiatric conditions based on this study alone. Decisions about starting or continuing semaglutide should weigh established indications, known side effects, contraindications and cost.

Randomized clinical trials are required to determine whether semaglutide or other GLP-1 therapies truly reduce the risk or severity of neurological and psychiatric conditions.

# Bottom line A large electronic-records study found associations between semaglutide use and lower rates of several neurological and psychiatric outcomes, with a possible dose-response pattern and effects that persist after accounting for weight loss. The design cannot prove causation. The findings justify further clinical trials but do not change current treatment recommendations for brain conditions.